Functional outcome measures in young, steroid-naïve boys with Duchenne muscular dystrophy

Mendell, 2012, Evidence-based path to newborn screening for Duchenne muscular dystrophy, Ann Neurol, 71, 304, 10.1002/ana.23528 Birnkrant, 2018, Diagnosis and management of Duchenne muscular dystrophy, part 3: primary care, emergency management, psychosocial care, and transitions of care across the lifespan, Lancet Neurol, 17, 445, 10.1016/S1474-4422(18)30026-7 van Ruiten, 2014, Improving recognition of Duchenne muscular dystrophy: a retrospective case note review, Arch Dis Child, 99, 1074, 10.1136/archdischild-2014-306366 Ciafaloni, 2009, Delayed diagnosis in Duchenne muscular dystrophy: data from the muscular dystrophy surveillance, tracking, and research network (MD STARnet), J Pediatr, 10.1016/j.jpeds.2009.02.007 Soim, 2018, Is there a delay in diagnosis of Duchenne muscular dystrophy among preterm-born males?, J Child Neurol, 10.1177/0883073818773029 Ricotti, 2016, The NorthStar Ambulatory Assessment in Duchenne muscular dystrophy: considerations for the design of clinical trials, J Neurol Neurosurg Psychiatry Magri, 2011, Genotype and phenotype characterization in a large dystrophinopathic cohort with extended follow-up, J Neurol, 258, 1610, 10.1007/s00415-011-5979-z Davidson, 2012, Deletions in the dystrophin gene predict loss of ambulation before 10 years of age in boys with Duchenne muscular dystrophy, Neuromuscul Disord, 22, 835, 10.1016/j.nmd.2012.06.111 Birnkrant, 2018, Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management, Lancet Neurol, 17, 211, 10.1016/S1474-4422(18)30024-3 Birnkrant, 2018, Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management, Lancet Neurol, 17, 347, 10.1016/S1474-4422(18)30025-5 McDonald, 2018, Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study, Lancet, 10.1016/S0140-6736(17)32160-8 Bushby, 2004, Report on the 124th ENMC international workshop. Treatment of Duchenne muscular dystrophy; defining the gold standards of management in the use of corticosteroids 2-4 April 2004, Naarden, The Netherlands, Neuromuscul Disord, 14, 526, 10.1016/j.nmd.2004.05.006 Muntoni, 2019, Categorising trajectories and individual item changes of the North Star Ambulatory Assessment in patients with Duchenne muscular dystrophy, PLoS ONE, 10.1371/journal.pone.0221097 Ricotti, 2016, The NorthStar Ambulatory Assessment in Duchenne muscular dystrophy: considerations for the design of clinical trials, J Neurol Neurosurg Psychiatry, 87, 149 Mercuri, 2012, International workshop on assessment of upper limb function in Duchenne Muscular Dystrophy. Rome, 15-16 February 2012, Neuromuscul Disord, 22, 1025, 10.1016/j.nmd.2012.06.006 Bushby K., Kirschner J., Luo X., Elfring G., Kroger H., Riebling P., et al. Results of North Star Ambulatory Assessments (NSAA) in the phase 3 ataluren confirmatory trial in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD) (I15.008). 2016. McDonald, 2017, Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial, Lancet, 10.1016/S0140-6736(17)31611-2 Mayhew, 2011, Moving towards meaningful measurement: rasch analysis of the North Star Ambulatory Assessment in Duchenne muscular dystrophy, Med Child Scott, 2012, Development of a functional assessment scale for ambulatory boys with Duchenne muscular dystrophy, Physiother Res Int, 17, 101, 10.1002/pri.520 Hobart, 2009, Improving the evaluation of therapeutic interventions in multiple sclerosis: the role of new psychometric methods, Heal Technol Assess, 13, 1 Goemans, 2013, Six-minute walk test: reference values and prediction equation in healthy boys aged 5 to12 years, PLoS ONE, 8, e84120, 10.1371/journal.pone.0084120 Guglieri, 2017, Developing standardized corticosteroid treatment for Duchenne muscular dystrophy, Contemp Clin Trials, 58, 34, 10.1016/j.cct.2017.04.008 Griggs, 1990, The use of pulmonary function testing as a quantitative measurement for therapeutic trials, Muscle Nerve, 13, 10.1002/mus.880131310 McDonald, 2010, The 6-minute walk test as a new outcome measure in Duchenne muscular dystrophy, Muscle Nerve, 41, 500, 10.1002/mus.21544 Crapo, 2002, ATS statement: guidelines for the six-minute walk test, Am J Respir Crit Care Med Schiava, 2022, Clinical and genetic characteristics in young, glucocorticoid-naive boys with Duchenne muscular dystrophy, Neurology, 98, e390, 10.1212/WNL.0000000000013122 Mazzone, 2009, Reliability of the North Star Ambulatory Assessment in a multicentric setting, Neuromuscul Disord, 19, 458, 10.1016/j.nmd.2009.06.368 McDonald, 2013, The 6-minute walk test and other clinical endpoints in Duchenne muscular dystrophy: reliability, concurrent validity, and minimal clinically important differences from a multicenter study, Muscle Nerve, 48, 357, 10.1002/mus.23905 Pane, 2014, Long term natural history data in ambulant boys with Duchenne muscular dystrophy: 36-month changes, PLoS ONE, 9, 10.1371/journal.pone.0108205 Mazzone, 2010, North Star Ambulatory Assessment, 6-minute walk test and timed items in ambulant boys with Duchenne muscular dystrophy, Neuromuscul Disord, 20, 712, 10.1016/j.nmd.2010.06.014